A Study for the Treatment of Mania Associated With Bipolar I Disorder in Children and Adolescents
This study has been completed.
Sponsor:
Abbott
Information provided by:
Abbott
ClinicalTrials.gov Identifier:
NCT00195780
First received: September 14, 2005
Last updated: June 29, 2007
Last verified: June 2007
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of the study is to evaluate the long-term safety profile of the Investigational Medication Depakote ER in the treatment of Bipolar I Disorder, manic or mixed episode, in children and adolescents ages 10-17.
| Condition | Intervention | Phase |
|---|---|---|
|
Bipolar I Disorder |
Drug: Divalproex Sodium (Depakote ER) |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | An Open-Label Study to Evaluate the Safety of Depakote ER in the Treatment of Mania Associated With Bipolar I Disorder in Children and Adolescents |
Resource links provided by NLM:
Further study details as provided by Abbott:
Eligibility| Ages Eligible for Study: | 10 Years to 17 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Subject is between 10 and 17 years of age, inclusive, on Day 1 and weighs at least 60 lbs (27 kg).
- Subject has a current psychiatric diagnosis of bipolar I disorder, manic or mixed episode, based on the K-SAD-PL interview and DSM-IV-TR criteria.
- Subject is an outpatient in a manic or mixed episode with a YMRS score of greater than or equal to 16 during Screening and at Day 1.
Exclusion Criteria:
- Has an Axis I disorder other than Attention Deficit Hyperactivity Disorder (ADHD), Obsessive Compulsive Disorder (OCD), Oppositional Defiant Disorder (ODD), Conduct Disorder (CD), Panic Disorder, Enuresis, Encopresis, Parasomnias, Agoraphobia, Specific Phobia, Social Phobia or Separation Anxiety Disorder; or subject has an Axis II disorder that would interfere with the subject's ability to comply with study procedures or confound interpretation of the study results. Subject meets DSM-IV-TR criteria for substance abuse within the month prior to Screening, or meets the criteria for substance dependence within the three months prior to Screening, or exhibits signs of drug or alcohol intoxication or withdrawal at Day 1.
- Is expected to require hospitalization for the current manic or mixed episode.
- Is violent, homicidal, or suicidal such that, in the opinion of the investigator, the subject is at significant imminent risk of hurting self or others.
- Has a history of a chronic or acute medical disorder that, in the opinion of the investigator, would preclude compliance with the protocol, or confound interpretation of the study results.
- Has a history of, or is suspected of having a seizure disorder.
- Has any central nervous system (CNS) neoplasm, CNS infection, demyelinating disease, degenerative neurological disease, or any progressive CNS disease.
- Has Platelet count less than or equal to 100,000/µL
- Has blood chemistry ALT/AST value(s) greater than or equal to 2 times upper limit of normal at screening.
- Is taking a protocol allowed medication for ADHD that has not been stable for at least 3 months prior to Day 1, or that, in the investigator's opinion, may be exacerbating mood symptoms.
- Requires anticoagulant drug therapy.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00195780
Show 29 Study Locations
Show 29 Study LocationsSponsors and Collaborators
Abbott
Investigators
| Study Director: | Global Medical Information | Abbott |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00195780 History of Changes |
| Other Study ID Numbers: | M03-647 |
| Study First Received: | September 14, 2005 |
| Last Updated: | June 29, 2007 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Abbott:
|
Bipolar I Disorder Depakote |
Additional relevant MeSH terms:
|
Valproic Acid Anticonvulsants Central Nervous System Agents Therapeutic Uses Pharmacologic Actions Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |
GABA Agents Neurotransmitter Agents Physiological Effects of Drugs Antimanic Agents Tranquilizing Agents Central Nervous System Depressants Psychotropic Drugs |
ClinicalTrials.gov processed this record on May 19, 2013